The global market for atrial fibrillation treatments is valued at USD 24.26 billion in 2024 and is projected to grow to USD 40.27 billion by 2034, with an annual growth rate of 5.2% from 2024 to 2034.
Download statistics of this report @ https://www.towardshealthcare.com/download-statistics/5120
Catheter ablation dominates the atrial fibrillation (AFib) treatment market, holding a 54% share in 2023 and is expected to grow rapidly. AFib cases are rising, particularly with aging populations, and the National Institutes of Health predict that the number of people affected could double or triple by 2050, emphasizing the need for better treatments.
Cardiovascular diseases, including AFib, cause about 17.9 million deaths annually worldwide. AFib, which causes irregular heartbeats and increases the risk of blood clots, can be triggered by factors like high blood pressure and obesity. Early detection and treatments like blood thinners and catheter ablation are crucial in managing the condition and preventing complications. As awareness and technology improve, the AFib treatment market continues to grow.
Our Table of Content (TOC) covers key healthcare market segments, materials, technologies and trends—helping you navigate market shifts and make informed decisions: https://www.towardshealthcare.com/table-of-content/atrial-fibrillation-treatment-market-sizing
Access exclusive insight now @ https://www.towardshealthcare.com/price/5120
We’ve prepared a service to support you. Please feel free to contact us at sales@towardshealthcare.com
Web: https://www.towardshealthcare.com
Visit Dental Specifics: https://www.towardsdental.com
Get the latest insights on industry segmentation with our Annual Membership: Get a Subscription
For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare
The medical imaging market is witnessing rapid expansion worldwide, and Europe is emerging as a key contributor to this global… Read More
The global continuous glucose monitoring devices market size is calculated at USD 4.97 in 2024. Living with diabetes in Canada… Read More
The surgical sutures market in the United States is showing steady and promising growth, and here’s why! 👇 👵👴 An… Read More
Azenta Life Sciences and Frenova, a division of Fresenius Medical Care and a leader in renal precision medicine, have announced… Read More
Zenara Pharma Private Limited, a leading Biophore company, has received final approval from the U.S. Food and Drug Administration (FDA)… Read More
Silexion Therapeutics Corp., a global clinical-stage biotech company specializing in RNA interference (RNAi) therapies, has announced outstanding new preclinical data… Read More